BSE: SYNGENE - Syngene International Limited

Rentabilität für sechs Monate: -18.52%
Dividendenrendite: +0.24%

Aktionsplan Syngene International Limited


Über das Unternehmen Syngene International Limited

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.

weitere details
The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

ISIN INE398R01022
Industry Biotechnology
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.2417
Дивиденд ао 1.25
Сайт https://www.syngeneintl.com
Цена ао 720.7
Preisänderung pro Tag: +0.0694% (720.7)
Preisänderung pro Woche: +2.36% (704.55)
Preisänderung pro Monat: +4.66% (689.1)
Preisänderung über 3 Monate: -14.8% (846.45)
Preisänderung über sechs Monate: -18.52% (885.15)
Preisänderung pro Jahr: +1.33% (711.75)
Preisänderung über 3 Jahre: +22.47% (588.9)
Preisänderung über 5 Jahre: +131.6% (311.4)
Preisänderung seit Jahresbeginn: -16.21% (860.75)

Unterschätzung

Name Bedeutung Grad
P/S 8.33 1
P/BV 6.59 1
P/E 55 2
EV/EBITDA 23.43 5
Gesamt: 4

Effizienz

Name Bedeutung Grad
ROA, % 8.29 3
ROE, % 11.98 4
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0.2417 0.6
DSI 1 10
Gesamt: 3.19

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0.141 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 67.48 8
Rentabilität Ebitda, % 30.38 5
Rentabilität EPS, % 29.09 4
Gesamt: 6.2

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Jonathan Brittan Hunt MD, CEO & Executive Director 84.75M 1969 (56 Jahre)
Mr. Sibaji Biswas CFO & Executive Director 34.14M
Krishnan G Head of Investor Relations N/A
Ms. Priyadarshini Mahapatra C.S. Head of Legal, Company Secretary & Compliance Officer 4.72M
Mr. Sandeep Nair Head of Corporate Communications N/A
Mr. Andrew Webster Chief Human Resources Officer N/A
Dr. Dhananjay Patankar Head of Pharmaceutical & Biopharmaceutical Development N/A
Mr. Purushottam Shashikant Singnurkar Head of Formulations Development N/A
Mr. Ajit Manocha Head of IT N/A
Dr. Jayashree Aiyar Ph.D. Head of Discovery Biology N/A

Adresse: India, Bengaluru, Velankani Technology Park - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.syngeneintl.com